Study guide
16.1 Maternal Physiology & Pharmacokinetics Across Trimesters
NBCRNA CRNA Certified Registered Nurse Anesthetist NCE
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Cardiovascular, Respiratory & CNS Physiology & Pathophysiology
1.1 Cardiovascular Physiology, Hemodynamics & Ischemic Heart Disease 1.2 Respiratory Physiology, Lung Volumes & Chronic Pulmonary Pathophysiology 1.3 Central & Autonomic Nervous System Physiology & Neurological Disorders
2 Chapter 2: Hepatorenal, Endocrine & Hematologic/Immune Systems
2.1 Renal Physiology, Glomerular Filtration & Acid-Base Balance 2.2 Hepatic Physiology, Drug Clearance & Gastrointestinal Considerations 2.3 Endocrine Disorders, Hematology, Coagulation & Immune Mechanisms
3 Chapter 3: Anesthetic Pharmacology: Inhalation Agents, Intravenous Anesthetics & Sedatives
3.1 Inhalation Anesthetics: Uptake, Distribution, Blood/Gas Solubility & MAC 3.2 Intravenous Hypnotics: Propofol, Etomidate, Ketamine & Barbiturates 3.3 Opioid Agonists/Antagonists, Benzodiazepines & Reversal Pharmacology
4 Chapter 4: Anesthetic Pharmacology: Neuromuscular Blockers, Local Anesthetics & Physics
4.1 Neuromuscular Blocking Agents & Reversal: Anticholinesterases vs Sugammadex 4.2 Local Anesthetics: Mechanism, Potency, Toxicity (LAST) & Vasoconstrictors 4.3 Applied Physics, Gas Laws, Fluid Dynamics & Anesthesia Mathematics
5 Chapter 5: Anesthesia Delivery Systems & Gas Supplies
5.1 Medical Gas Supply Systems, Cylinders, Regulators & Safety Index Systems (PISS/DISS) 5.2 Anesthesia Machine High, Intermediate & Low Pressure Systems & Failsafe Mechanisms 5.3 Vaporizer Technology: Variable-Bypass vs Desflurane Vaporizers & Machine Checkout
6 Chapter 6: Breathing Circuits, CO2 Absorption & Ventilators
6.1 Breathing Circuits: Circle System, Mapleson Classifications & Dead Space 6.2 Carbon Dioxide Absorption: Soda Lime Chemistry, Desiccation, Carbon Monoxide & Compound A 6.3 Anesthesia Ventilators, Pressure/Volume Modes, APL Valves & Waste Gas Scavenging
7 Chapter 7: Airway Equipment & Advanced Airway Instrumentation
7.1 Face Masks, Supraglottic Airways (LMA Types) & Endotracheal Tubes 7.2 Direct Laryngoscopy (Mac/Miller) & Video Laryngoscopy 7.3 Fiberoptic Intubation, Bronchial Blockers, Double-Lumen Tubes & Surgical Airways
8 Chapter 8: Patient Monitoring, Hemodynamics & Electrosurgical Safety
8.1 Noninvasive Monitoring: Pulse Oximetry, Capnography Waveforms & Temperature 8.2 Invasive Hemodynamics: Arterial Lines, CVP & Pulmonary Artery Catheters 8.3 Neuromuscular Monitoring (TOF/PTC), Depth of Anesthesia (EEG/BIS) & Electrical Safety
9 Chapter 9: Preoperative Assessment, Risk Stratification & Preparation
9.1 Preoperative History, Physical Examination & ASA Physical Status Classification 9.2 Cardiac & Pulmonary Risk Stratification, Diagnostic Testing & Optimization 9.3 Preoperative Fasting Guidelines, Aspiration Prophylaxis & Premedication
10 Chapter 10: Fluid Management, Blood Component Therapy & Coagulation Monitoring
10.1 Crystalloids vs Colloids, Maintenance & Deficit Calculations 10.2 Blood Component Therapy, Transfusion Triggers & Massive Transfusion Protocols 10.3 Point-of-Care Coagulation: TEG, ROTEM & Perioperative Coagulopathies
11 Chapter 11: Airway Management Strategies & Difficult Airway Algorithms
11.1 Difficult Airway Assessment: Mallampati, Cormack-Lehane & Airway Predictors 11.2 ASA Difficult Airway Algorithm: Anticipated vs Unanticipated Difficult Airway 11.3 "Cannot Intubate, Cannot Oxygenate" (CICO) & Emergency Front-of-Neck Access (eFONA)
12 Chapter 12: General Anesthesia: Induction, Maintenance, Emergence & TIVA
12.1 Rapid Sequence Induction (RSI), Cricoid Pressure & Intubation Protocols 12.2 Balanced Anesthesia vs Total Intravenous Anesthesia (TIVA) Principles 12.3 Emergence, Extubation Criteria, Deep vs Awake Extubation & Laryngospasm
13 Chapter 13: Regional Anesthesia: Neuraxial Blocks
13.1 Spinal Anesthesia: Anatomy, Physiology, High Spinal & Complications 13.2 Epidural & Combined Spinal-Epidural (CSE) Techniques & PDPH 13.3 Neuraxial Anticoagulation Guidelines (ASRA) & Epidural Hematoma
14 Chapter 14: Regional Anesthesia: Peripheral Nerve Blocks & Ultrasound Guidance
14.1 Upper Extremity Peripheral Nerve Blocks: Interscalene, Supraclavicular, Axillary 14.2 Lower Extremity & Truncal Blocks: Femoral, Sciatic, TAP & ESP Blocks 14.3 Ultrasound Physics, Needle Visualization & LAST Rescue Protocols
15 Chapter 15: Perioperative Safety, Positioning, PACU, Ethics & Professional Practice
15.1 Surgical Positioning Complications: Nerve Injuries & Physiologic Changes 15.2 PACU Discharge Criteria, PONV Management, Hypoxemia & Emergence Delirium 15.3 Malignant Hyperthermia Protocol & Operating Room Crisis Management 15.4 CRNA Ethics, Informed Consent, Scope of Practice & Wellness Initiatives
16 Chapter 16: Obstetric & Gynecologic Anesthesia
16.1 Maternal Physiology & Pharmacokinetics Across Trimesters 16.2 Labor Analgesia & Anesthesia for Cesarean Delivery 16.3 Obstetric Emergencies: Preeclampsia, Hemorrhage & Amniotic Fluid Embolism 16.4 Nonobstetric Surgery in the Pregnant Patient
17 Chapter 17: Pediatric Anesthesia
17.1 Pediatric Anatomy, Physiology, Airway & Developmental Pharmacology 17.2 Pediatric Induction, Maintenance, Fluids & Emergence Agitation 17.3 Pediatric Respiratory Emergencies: Croup, Epiglottitis & Laryngospasm
18 Chapter 18: Geriatric, Bariatric & Ambulatory Anesthesia
18.1 Geriatric Physiology, Pharmacodynamics & Postoperative Delirium/POCD 18.2 Bariatric Anesthesia: Obesity Hypoventilation, OSA & Dosing Adjustments 18.3 Ambulatory Surgery Selection Criteria & ERAS Protocols
19 Chapter 19: Cardiac, Vascular & Thoracic Anesthesia
19.1 Valvular Heart Disease, CAD & Cardiopulmonary Bypass Management 19.2 Vascular Anesthesia: Carotid Endarterectomy & Aortic Cross-Clamping 19.3 Thoracic Anesthesia: One-Lung Ventilation & Hypoxic Pulmonary Vasoconstriction
20 Chapter 20: Neurosurgical, Intra-Abdominal, Extrathoracic, Head/Neck & Trauma Anesthesia
20.1 Neurosurgical Anesthesia: ICP Dynamics, Craniotomy & Venous Air Embolism 20.2 Intra-Abdominal, Laparoscopy & Endocrine Tumor Anesthesia (Pheochromocytoma, Carcinoid) 20.3 ENT/Shared Airway, Extrathoracic Procedures & Trauma/Burn Resuscitation
21 Chapter 21: Neurologic, Gastrointestinal & Substance-Related Pathophysiology and Pharmacology
21.1 Neurodegenerative & Demyelinating Disease and Antiparkinsonian Pharmacology 21.2 Gastrointestinal & Exocrine Pancreatic Disorders: Esophageal, Gastric, Pancreatitis & Malabsorption 21.3 Cannabinoids, Herbal Remedies & Dietary Supplements
22 Chapter 22: Imaging Safety, Patient Warming & Infusion Technology
22.1 Fluoroscopy, Radiography & Radiation Safety in Anesthetizing Locations 22.2 Patient Warming Equipment & Rapid Infusion Devices
23 Chapter 23: Pain Medicine: Theory, Chronic Pain & Interventional Procedures
23.1 Pain Theory: Nociception, Sensitization & Chronic Pain Pathophysiology 23.2 Chronic Pain Management, Medication-Assisted Therapy & the Opioid-Tolerant Patient 23.3 Interventional Pain Procedures & Anesthesia for Pain Management Cases
24 Chapter 24: Professional Practice: Research Ethics, Error Disclosure & Provider Infection Control
24.1 Research Ethics, IRB Oversight & Protection of Human Subjects 24.2 Disclosure of Errors and Injuries, Adverse Event Reporting & Just Culture 24.3 Provider Infection Control: PPE, Air Handling & Occupational Exposure
25 Chapter 25: Neurosurgical Subspecialty Procedures
25.1 Cerebral Aneurysm Clipping, AVM Resection & Subarachnoid Hemorrhage 25.2 Transsphenoidal Hypophysectomy & Pituitary Surgery 25.3 Stereotactic Procedures, Deep Brain Stimulation & Awake Craniotomy 25.4 CSF Diversion, Burr Holes, Ventriculoperitoneal Shunts & Decompressive Craniectomy
26 Chapter 26: Head, Neck, Nasal, Dental & Ophthalmic Anesthesia
26.1 Nasal & Sinus Surgery, Nasotracheal Intubation & Craniofacial Procedures 26.2 Dental, Orthodontic, Oral-Maxillofacial & Ophthalmic Anesthesia 26.3 Neck Tumors, Radical Neck Dissection, Lymph Node Biopsy & Thyroid/Parathyroid Surgery
27 Chapter 27: Orthopedic & Extremity Anesthesia
27.1 Total Joint Arthroplasty, Bone Cement Implantation Syndrome & Tourniquet Physiology 27.2 Closed Reduction, Hand and Foot Procedures & Intravenous Regional (Bier) Block
28 Chapter 28: Non-Operating-Room Anesthesia: Interventional, Imaging & Radiation Therapy
28.1 Interventional and Neurointerventional Radiology Anesthesia 28.2 Radiation Therapy, Diagnostic Imaging & MRI-Suite Anesthesia
29 Chapter 29: Special Populations: Substance Use Disorder, Immunocompromised & Oncology Patients
29.1 Acute Intoxication, Withdrawal Syndromes & Perioperative Complications 29.2 Anesthesia for the Immunocompromised & Oncology Patient
16.1 Maternal Physiology & Pharmacokinetics Across Trimesters
Key Takeaways Explain This Topic AI
Maternal plasma volume expands by ~50% while red cell mass increases by only ~20-30%, creating a physiologic hemodilution anemia (baseline Hgb 11-12 g/dL, Hct 33-35%).
Cardiac output rises 40-50% at term (and up to 80% immediately postpartum from autotransfusion); aortocaval compression develops from 20 weeks gestation onward, requiring 15° left uterine displacement (LUD) to prevent severe reductions in venous return and uteroplacental hypoperfusion.
Minute ventilation increases by ~50% via progesterone-driven central stimulation, decreasing maternal baseline PaCO2 to 28-32 mmHg with compensatory renal bicarbonate reduction to 18-22 mEq/L (maintaining pH 7.40-7.44).
Functional Residual Capacity (FRC) decreases by 20-30% at term while oxygen consumption (VO2) increases by 20-40%, precipitating rapid arterial desaturation during induction and apnea.
Inhalational anesthetic MAC decreases by 30-40% and local anesthetic dosage requirements for neuraxial block decrease by 25-40% due to progesterone-mediated neural sensitivity, decreased CSF volume, and epidural venous plexus engorgement.
Last updated: August 2026
16.1 Maternal Physiology & Pharmacokinetics Across Trimesters
Pregnancy elicits widespread anatomical and physiological adaptations designed to sustain the developing fetus and prepare the parturient for delivery. For the nurse anesthetist, these changes dramatically alter airway management, cardiopulmonary reserve, drug pharmacokinetics, and maternal-fetal safety thresholds.
1. Cardiovascular System Alterations
Cardiovascular remodeling begins during the first trimester, peaks late in the second to early third trimester, and undergoes dynamic fluctuations during labor and the immediate postpartum period. +---------------------------------------------------------------------------------------------------------+
- | MATERNAL CARDIOVASCULAR ADAPTATIONS AT TERM |
- +----------------------------+-----------------------+----------------------------------------------------+
- | Parameter | Percentage Change | Physiologic Mechanism & Clinical Significance |
- +----------------------------+-----------------------+----------------------------------------------------+
- | **Intravascular Volume** | +35% to +45% overall | • Plasma volume expands by ~50% (1000-1500 mL) |
- | | | • Erythrocyte mass expands by ~20% to 30% (300 mL) |
- | | | • Result: **Physiologic Anemia of Pregnancy** |
- | | | (Normal term Hgb: 11-12 g/dL; Hct: 33-35%) |
- +----------------------------+-----------------------+----------------------------------------------------+
- | **Cardiac Output (CO)** | +40% to +50% at term | • Stroke Volume (SV) increases by ~30% |
- | | | • Heart Rate (HR) increases by ~15% to 25% (10-20 bpm)|
- | | | • Left ventricular hypertrophy & chamber dilation |
- +----------------------------+-----------------------+----------------------------------------------------+
- | **Systemic Vascular | -20% to -30% | • Low-resistance uteroplacental vascular shunt |
- | Resistance (SVR)** | | • Vasodilation via Prostacyclin (PGI2), Nitric |
- | | | Oxide (NO), and circulating relaxin/estrogen |
- +----------------------------+-----------------------+----------------------------------------------------+
- | **Pulmonary Vascular | -30% to -40% | • Significant reduction in pulmonary resistance |
- | Resistance (PVR)** | | • Accommodates massive increase in right heart CO |
- +----------------------------+-----------------------+----------------------------------------------------+
- | **Blood Pressure (MAP)** | ↓ Mid-trimester, | • SBP and DBP nadir at 24-28 weeks (5-10 mmHg drop)|
- | | Normalizes at Term | • Normalizes toward pre-pregnancy baseline at term |
- +----------------------------+-----------------------+----------------------------------------------------+
- | **Central Venous / PAOP** | Unchanged | • Unchanged despite massive intravascular expansion|
- | | | due to profound vascular compliance/capacitance |
- +----------------------------+-----------------------+----------------------------------------------------+
- Hemodynamic Fluctuations During Labor & Postpartum Autotransfusion
Cardiac output surges dynamically throughout labor and delivery above pre-labor baseline levels:
First Stage (Latent/Active Labor): CO increases by + 15 % +15\% + 15% to + 30 % +30\% + 30% during contractions.
Second Stage (Pushing / Expulsive): CO increases by + 45 % +45\% + 45% to + 50 % +50\% + 50% due to pain, sympathetic activation, and maternal expulsive efforts.
Immediate Postpartum Period (The Hemodynamic Peak): CO surges by + 60 % +60\% + 60% to + 80 % +80\% + 80% (up to 10 − 12 L/min 10 - 12 \text{ L/min} 10 − 12 L/min ) within minutes of delivery. This occurs because of:
Uterine Autotransfusion: The contracted, empty uterus expels approximately 300 − 500 mL 300 - 500 \text{ mL} 300 − 500 mL of blood into the maternal venous circulation.
Relief of Caval Compression: Complete decompression of the inferior vena cava (IVC) immediately restores full venous return to the right heart.
Caution
The Postpartum Heart Failure Trap: Parturients with pre-existing stenotic valvular heart disease (especially Mitral Stenosis or Aortic Stenosis ) or cardiomyopathy are at the absolute highest risk for acute pulmonary edema and cardiovascular collapse immediately following placental delivery , not during induction or labor! [LABOR & POSTPARTUM CARDIAC OUTPUT TRAJECTORY]
- Cardiac Output (% Above Pre-Pregnancy Baseline)
- 100% | /\ [Immediate Postpartum Peak: +80%]
- 80% | / \ (Autotransfusion + IVC Relief)
- 60% | /\ (Stage 2) \
- 40% | ========================= (Pushing) \========== (Normalizes in 2-4 wks)
- 20% | / (Term Baseline: +40-50%)
- 0% |______/
- Non-Preg 1st Tri 2nd Tri 3rd Tri Stage 1 Stage 2 Postpartum
- Aortocaval Compression Syndrome (Supine Hypotensive Syndrome)
From the 20th week of gestation onward , the gravid uterus compresses both the inferior vena cava and the descending abdominal aorta when the parturient is in the supine position.
Vena Caval Compression: Obstructs venous return from the lower extremities, drastically reducing right ventricular end-diastolic volume, stroke volume, and cardiac output by up to 20 − 30 % 20 - 30\% 20 − 30% . Symptoms include lightheadedness, diaphoresis, nausea, tachycardia, and profound hypotension.
Aortic Compression: Compresses the aorta above the bifurcation, decreasing arterial perfusion pressure to the lower extremities and, critically, to the uterine arteries.
Clinical Mandate: Always establish 15 ∘ 15^\circ 1 5 ∘ Left Uterine Displacement (LUD) or place a firm wedge under the right hip in every parturient ≥ 20 \ge 20 ≥ 20 weeks gestation during transport, regional anesthesia placement, surgery, and cardiopulmonary resuscitation. [AORTOCAVAL COMPRESSION MECHANICS]
- SUPINE (PATHOLOGIC) LEFT UTERINE DISPLACEMENT (LUD)
- =================== ===============================
- [Gravid Uterus] [Gravid Uterus]
- | | /
- v v / (Tilted 15° Left)
- [IVC] [AORTA] v
- (Flattened/ (Compressed/ [IVC] [AORTA]
- Occluded) Hypoperfused) (Patent) (Patent)
- | |
- v v
- ↓ Preload ↓ Uteroplacental Flow
- ↓ CO & BP → Fetal Bradycardia
- Uteroplacental Perfusion Dynamics
Uterine blood flow (UBF) increases ten-fold from 50 − 100 mL/min 50 - 100 \text{ mL/min} 50 − 100 mL/min in the non-pregnant state to 700 − 900 mL/min 700 - 900 \text{ mL/min} 700 − 900 mL/min at term, accounting for 10 − 12 % 10 - 12\% 10 − 12% of total cardiac output. Crucially, the uteroplacental vascular bed is maximally dilated with ZERO autoregulation . Uterine Blood Flow (UBF) = Uterine Arterial Pressure (UAP) − Uterine Venous Pressure (UVP) Uterine Vascular Resistance (UVR) \text{Uterine Blood Flow (UBF)} = \frac{\text{Uterine Arterial Pressure (UAP)} - \text{Uterine Venous Pressure (UVP)}}{\text{Uterine Vascular Resistance (UVR)}} Uterine Blood Flow (UBF) = Uterine Vascular Resistance (UVR) Uterine Arterial Pressure (UAP) − Uterine Venous Pressure (UVP)
Clinical determinants affecting UBF:
Decreased Perfusion Pressure (UAP - UVP): Caused by maternal systemic hypotension (sympathectomy from spinal/epidural, hemorrhage, aortocaval compression) or elevated uterine venous pressure (vena caval compression, Valsalva pushing, hypertonic uterine contractions).
Increased Vascular Resistance (UVR): Caused by endogenous catecholamines (maternal anxiety, severe labor pain), exogenous alpha-1 agonists in high doses, local anesthetic systemic toxicity (LAST), or preeclampsia/vasospasm.
Note
Phenylephrine vs. Ephedrine in Obstetrics: Historical teaching favored ephedrine due to concerns that phenylephrine-induced alpha-1 vasoconstriction would compromise UBF. However, modern evidence demonstrates that Phenylephrine is the first-line vasopressor of choice for post-spinal hypotension in obstetrics. Phenylephrine maintains maternal blood pressure while producing superior fetal acid-base profiles (higher umbilical artery pH and lower base deficit). Ephedrine crosses the placenta readily, stimulates fetal metabolism via beta-adrenergic receptors, and induces fetal lactic acidosis.
2. Respiratory System Alterations
Pregnancy-induced hormonal and mechanical changes dramatically alter maternal pulmonary mechanics, lung volumes, and arterial blood gas values. +---------------------------------------------------------------------------------------------------------+
- | MATERNAL RESPIRATORY ALTERATIONS AT TERM |
- +----------------------------+-----------------------+----------------------------------------------------+
- | Parameter | Percentage Change | Clinical Significance & Mechanistic Detail |
- +----------------------------+-----------------------+----------------------------------------------------+
- | **Minute Ventilation (VE)**| +50% at term | • Tidal Volume (VT) increases +40% to 45% |
- | | | • Respiratory Rate (RR) increases +10% to 15% |
- | | | • Driven by progesterone stimulating medullary ctr |
- +----------------------------+-----------------------+----------------------------------------------------+
- | **Functional Residual | -20% to -30% | • Diaphragm displaced cephalad by ~4 cm |
- | Capacity (FRC)** | (up to -40% supine) | • Expiratory Reserve Volume (ERV) drops -20% to -25%|
- | | | • Residual Volume (RV) drops -15% to -20% |
- +----------------------------+-----------------------+----------------------------------------------------+
- | **Vital Capacity (VC)** | Unchanged | • Compensatory widening of subcostal angle |
- | **Total Lung Cap. (TLC)** | Unchanged (-0% to -5%)| (from 68° to 103°) preserves thoracic compliance |
- +----------------------------+-----------------------+----------------------------------------------------+
- | **Oxygen Consumption (VO2)**| +20% to +40% at term | • Increased metabolic demand of fetus, placenta, |
- | | (+100% in labor) | and maternal cardiac/renal/respiratory work |
- +----------------------------+-----------------------+----------------------------------------------------+
- | **Airway Resistance (Raw)**| -35% to -50% | • Progesterone-mediated bronchial smooth muscle |
- | | | relaxation decreases total airway resistance |
- +----------------------------+-----------------------+----------------------------------------------------+
- Maternal Blood Gas Equilibrium: Compensated Respiratory Alkalosis
Progesterone acts directly as a respiratory stimulant on the central medullary chemoreceptors, shifting the carbon dioxide response curve to the left and increasing its slope. As a result, the pregnant patient chronically hyperventilates. +---------------------------------------------------------------------------------------+
- | ARTERIAL BLOOD GAS VALUES: PREGNANT VS. NON-PREGNANT |
- +--------------------+----------------------------+-------------------------------------+
- | Blood Gas Variable | Non-Pregnant Baseline | Term Pregnant Baseline |
- +--------------------+----------------------------+-------------------------------------+
- | **pH** | 7.35 – 7.45 (Mean: 7.40) | **7.40 – 7.44** (Mildly alkalotic) |
- | **PaCO₂** | 35 – 45 mmHg (Mean: 40) | **28 – 32 mmHg** (Chronic hypocapnia)|
- | **PaO₂** | 80 – 100 mmHg | **100 – 106 mmHg** (1st Tri); 95-100 (3rd Tri)|
- | **Serum HCO₃⁻** | 22 – 26 mEq/L (Mean: 24) | **18 – 22 mEq/L** (Renal excretion) |
- | **Base Excess** | -2 to +2 mEq/L | **-3 to -2 mEq/L** |
- | **P50 (Hb-O2)** | 26.7 mmHg | **30 mmHg** (Right-shifted curve) |
- +--------------------+----------------------------+-------------------------------------+
Physiologic Significance of Maternal P50 Right-Shift: Maternal hemoglobin P50 increases from 26.7 mmHg 26.7 \text{ mmHg} 26.7 mmHg to 30 mmHg 30 \text{ mmHg} 30 mmHg due to increased 2,3-DPG. This rightward shift facilitates oxygen unloading across the placenta. Conversely, Fetal Hemoglobin (HbF) has a P50 of 19 mmHg 19 \text{ mmHg} 19 mmHg (left-shifted curve due to poor binding to 2,3-DPG), creating a steep partial pressure gradient that pulls oxygen from maternal blood into fetal circulation ( The Double Bohr Effect ).
Mechanism of Rapid Maternal Arterial Desaturation
During induction of general anesthesia and apnea, parturients desaturate at an alarming rate compared to non-pregnant adults. The safe apnea time (time until S p O 2 < 90 % SpO_2 < 90\% Sp O 2 < 90% ) decreases from ≈ 8 minutes \approx 8 \text{ minutes} ≈ 8 minutes in healthy non-pregnant adults to < 2 − 3 minutes < 2 - 3 \text{ minutes} < 2 − 3 minutes in term parturients. Desaturation Rate ∝ Oxygen Consumption ( V ˙ O 2 ) Functional Residual Capacity ( F R C ) \text{Desaturation Rate} \propto \frac{\text{Oxygen Consumption } (\dot{V}O_2)}{\text{Functional Residual Capacity } (FRC)} Desaturation Rate ∝ Functional Residual Capacity ( FRC ) Oxygen Consumption ( V ˙ O 2 )
Diminished Oxygen Reservoir (FRC): FRC decreases by 20 − 30 % 20 - 30\% 20 − 30% upright and up to 40 % 40\% 40% supine. FRC falls below Closing Capacity (CC) in up to 50 % 50\% 50% of parturients when supine, causing small airway closure and shunt ( V / Q < 1 V/Q < 1 V / Q < 1 ) during normal tidal breathing.
Accelerated Oxygen Consumption ( V O 2 VO_2 V O 2 ): Metabolic oxygen demand increases by 20 − 40 % 20 - 40\% 20 − 40% at rest and > 100 % >100\% > 100% during active labor.
Clinical Action: Thorough preoxygenation is mandatory: 8 vital capacity breaths of 100 % O 2 100\% \text{ O}_2 100% O 2 over 60 seconds (or 3-5 minutes of tidal breathing at > 10 L/min >10 \text{ L/min} > 10 L/min ) with an airtight mask seal, supplemented by continuous high-flow nasal cannula oxygen (THRIVE) during airway instrumentation.
The Obstetric Airway: Capillary Engorgement & Difficult Intubation
Estrogen induces profound mucosal hyperemia, glandular hyperactivity, and tissue edema throughout the upper respiratory tract (nasopharynx, oropharynx, larynx, and false vocal cords).
Difficult Intubation Incidence: Difficult or failed tracheal intubation is 8 to 10 times higher in obstetrics ( 1 : 250 − 1 : 300 1:250 - 1:300 1 : 250 − 1 : 300 ) than in the general surgical population ( 1 : 2000 1:2000 1 : 2000 ).
Airway Management Directives:
Avoid nasal instrumentation (nasal airways, nasogastric tubes, nasal ETTs) due to extreme vascularity and risk of severe epistaxis.
Downsize the endotracheal tube: use a 6.0 to 6.5 mm ID cuffed ETT (standard 7.0-8.0 tubes may cause vocal cord trauma or fail to pass through the narrowed glottis).
Utilize a short-handled laryngoscope blade to prevent the handle from impinging against hypertrophied breast tissue during insertion.
3. Gastrointestinal, Hepatic, and Renal Adaptations +---------------------------------------------------------------------------------------------------------+
- | GASTROINTESTINAL & HEPATORENAL ALTERATIONS |
- +---------------------+-------------------------------+---------------------------------------------------+
- | Organ System | Physiologic Alteration | Clinical Implications for Anesthesia |
- +---------------------+-------------------------------+---------------------------------------------------+
- | **Gastrointestinal**| • Progesterone relaxes Lower | • **High aspiration risk:** All parturients |
- | | Esophageal Sphincter (LES) | $\ge 14-16$ weeks are considered "full stomach" |
- | | • Stomach displaced cephalad | • Barrier pressure ($P_{LES} - P_{gastric}$) drops|
- | | • Placental gastrin secretion | • Gastric pH is lower; volume is increased |
- | | • Delayed emptying in labor | • Opioids/pain further halt gastric motility |
- +---------------------+-------------------------------+---------------------------------------------------+
- | **Hepatic** | • Serum albumin drops ~20-30% | • Increased free unbound fraction of basic/acidic |
- | | • Plasma pseudocholinesterase | drugs (bupivacaine, rocuronium, diazepam) |
- | | activity drops by ~25-30% | • Prolonged succinylcholine duration is rare |
- | | • Alkaline Phosphatase rises | because volume of distribution is also expanded |
- | | 2-3x (placental isoenzyme) | • AST, ALT, Bilirubin, LDH do NOT change normally |
- +---------------------+-------------------------------+---------------------------------------------------+
- | **Renal** | • Renal Blood Flow rises +60% | • **Lower baseline Serum Creatinine (0.4-0.6 mg/dL|
- | | • GFR increases by +50% | and BUN (8-10 mg/dL)**; Cr >0.8 is abnormal |
- | | • Glycosuria & proteinuria | • Proteinuria up to 300 mg/24h is normal |
- | | (mild, up to 300 mg/day) | • Rapid renal clearance of hydrophilic drugs |
- +---------------------+-------------------------------+---------------------------------------------------+
- 4. Hematology & The Hypercoagulable State
Pregnancy is a state of compensated, physiological hypercoagulability designed to limit peripartum hemorrhage. Estrogen drives enhanced hepatic production of procoagulant clotting factors while decreasing natural anticoagulant pathways. +---------------------------------------------------------------------------------------------------------+
- | MATERNAL COAGULATION PROFILE AT TERM |
- +--------------------------------------+------------------------------------------------------------------+
- | Coagulation Factor Alteration | Clinical Value & Physiologic Context |
- +--------------------------------------+------------------------------------------------------------------+
- | **Factor I (Fibrinogen) ↑↑** | • Increases +50% to +100% (**Normal at Term: 400 - 650 mg/dL**) |
- | | • Level < 200 mg/dL represents critical consumption / DIC |
- +--------------------------------------+------------------------------------------------------------------+
- | **Factors VII, VIII, IX, X, XII ↑** | • Significant elevation in intrinsic & extrinsic clotting factors|
- | **von Willebrand Factor (vWF) ↑** | • Increases 2- to 3-fold, reducing bleeding in mild vWD |
- +--------------------------------------+------------------------------------------------------------------+
- | **Protein S Activity ↓↓** | • Significant reduction in free active Protein S |
- | **Activated Protein C Resistance ↑** | • Physiologic resistance to APC develops in late pregnancy |
- | **Antithrombin III (ATIII) ↓/↔** | • Borderline decrease or normal; relative deficiency |
- +--------------------------------------+------------------------------------------------------------------+
- | **Fibrinolysis ↓** | • Placental PAI-1 and PAI-2 suppress clot lysis until delivery |
- +--------------------------------------+------------------------------------------------------------------+
- | **Thromboembolism Risk** | • **5- to 6-fold higher risk** of deep vein thrombosis and PE |
- +--------------------------------------+------------------------------------------------------------------+
Gestational Thrombocytopenia: Platelet counts drop progressively during pregnancy in ≈ 8 % \approx 8\% ≈ 8% of healthy women due to hemodilution and accelerated platelet consumption in the uteroplacental bed. A platelet count between 100 , 000 − 150 , 000 / mm 3 100,000 - 150,000 /\text{mm}^3 100 , 000 − 150 , 000/ mm 3 without systemic symptoms or bleeding history is benign gestational thrombocytopenia and does not preclude neuraxial anesthesia.
- 5. Obstetric Pharmacokinetics & Placental Drug Transfer
- Anesthetic Sensitivity & Reduced Dosing Requirements
Inhalational Anesthetics: Minimum Alveolar Concentration (MAC) is reduced by 30% to 40% across all volatile agents starting as early as 8-12 weeks gestation. This is mediated by increased progesterone levels and elevated central β \beta β -endorphin activity enhancing GABAergic transmission. Furthermore, the elevated V A / F R C V_A / FRC V A / FRC ratio accelerates both inhalational induction and emergence.
Neuraxial Local Anesthetics: Spinal and epidural local anesthetic dose requirements are reduced by 25% to 40% due to:
Epidural Space Compression: IVC compression engorges the epidural venous plexus (Batson's plexus), reducing both the volume of the epidural space and the volume of lumbar CSF within the subarachnoid space.
Enhanced Neural Sensitivity: Progesterone alters neural axonal membrane lipid dynamics, making sodium channels more susceptible to local anesthetic blockade.
Spinal Curvature: Exaggerated lumbar lordosis promotes enhanced cephalad spread of hyperbaric intrathecal solutions.
Principles of Placental Drug Transfer
Placental transfer occurs primarily via passive simple diffusion , governed by Fick's Law: Rate of Transfer = K ⋅ A ⋅ ( C m − C f ) D \text{Rate of Transfer} = \frac{K \cdot A \cdot (C_m - C_f)}{D} Rate of Transfer = D K ⋅ A ⋅ ( C m − C f )
Where K K K is diffusion constant, A A A is surface area, ( C m − C f ) (C_m - C_f) ( C m − C f ) is concentration gradient, and D D D is membrane thickness. +---------------------------------------------------------------------------------------------------------+
- | PLACENTAL DRUG CROSSING CHARACTERISTICS |
- +--------------------------------------+------------------------------------------------------------------+
- | Physico-Chemical Factor Favoring Transfer | Physico-Chemical Factor Preventing Transfer |
- +--------------------------------------+------------------------------------------------------------------+
- | • **Low Molecular Weight (< 500 Da)** | • **High Molecular Weight (> 1000 Da)** |
- | • **High Lipid Solubility (Lipophilic)**| • **High Water Solubility / High Ionization** |
- | • **Low Maternal Protein Binding** | • **High Maternal Protein Binding** |
- | • **Non-Ionized Molecular Fraction** | • **Highly Quaternary Ammonium Structure** |
+--------------------------------------+------------------------------------------------------------------+ +---------------------------------------------------------------------------------------------------------+
- | DRUG CLASSIFICATION BY PLACENTAL TRANSFER |
- +------------------------------------+--------------------------------------------------------------------+
- | DRUGS THAT CROSS THE PLACENTA | DRUGS THAT DO NOT CROSS (or cross negligibly) |
- | *(Low MW, Lipophilic, Non-ionized)*| *(Mnemonic: **"He Is Going Nowhere Soon"**)* |
- +------------------------------------+--------------------------------------------------------------------+
- | • **Volatile Anesthetics** (all) | • **H**eparin / LMWH (High MW, polar polyanion) |
- | • **Propofol, Etomidate, Ketamine**| • **I**nsulin (High MW protein, 5800 Da) |
- | • **Opioids** (Fentanyl, Morphine) | • **G**lycopyrrolate (Quaternary amine, charged, polar) |
- | • **Benzodiazepines** (Midazolam) | • **N**euromuscular Blockers: Succinylcholine, Rocuronium, |
- | • **Local Anesthetics** (Lido, Bupi)| Vecuronium, Cisatracurium (Fully ionized quaternary ammoniums) |
- | • **Atropine & Scopolamine** | • **S**ugammadex (Cyclodextrin macromolecule, 2178 Da) |
- | • **Beta-Blockers** (Labetalol) | |
- | • **Ephedrine & Clonidine** | |
- +------------------------------------+--------------------------------------------------------------------+
- The Clinical Phenomenon of Fetal Ion Trapping
Local anesthetics (e.g., lidocaine, bupivacaine) and opioids are weak bases . In the maternal circulation ( p H ≈ 7.40 pH \approx 7.40 p H ≈ 7.40 ), a significant portion of the drug exists in the un-ionized, lipid-soluble state ( B B B ), which readily diffuses across the placental syncytiotrophoblast.
If the fetus is distressed, asphyxiated, or acidemic ( p H ≈ 7.10 − 7.20 pH \approx 7.10 - 7.20 p H ≈ 7.10 − 7.20 ), the lower fetal pH drives the equilibrium toward the ionized conjugate acid state ( B H + BH^+ B H + ) : B + H + ⇌ B H + ( Ionized, lipid-insoluble form ) B + H^+ \rightleftharpoons BH^+ \quad (\text{Ionized, lipid-insoluble form}) B + H + ⇌ B H + ( Ionized, lipid-insoluble form )
Because ionized molecules cannot diffuse back across lipid cell membranes, the drug becomes trapped within the fetal circulation , leading to toxic accumulation, neonatal myocardial depression, and severe neurobehavioral depression.